Efficient α and β− radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model-Reference-Cited by-同舟云学术

Efficient α and β− radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model

Published:2024-09-06 Issue: Volume: Page:
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Ceuppens Hannelore^ORCID,Pombo Antunes Ana Rita,Navarro Laurent,Ertveldt Thomas,Berdal Marion,Nagachinta Surasa,De Ridder Kirsten,Lahoutte Tony,Keyaerts Marleen,Devoogdt Nick,Goyvaerts Cleo,D’Huyvetter Matthias,Breckpot Karine

Funder

Innoviris

Vrije Universiteit Brussel

Kom op tegen Kanker

Stichting Wetenschappelijk Onderzoek Oogziekenhuis

Fonds Wetenschappelijk Onderzoek

Bijzonder Onderzoeksfonds UGent

Eutopia Foundation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06914-4.pdf

Reference42 articles.

1. Funeh CN, Bridoux J, Ertveldt T, De Groof TWM, Chigoho DM, Asiabi P, et al. Optimizing the Safety and Efficacy of Bio-radiopharmaceuticals for Cancer Therapy. Pharmaceutics. 2023;15. https://doi.org/10.3390/pharmaceutics15051378.

2. Rondon A, Rouanet J, Degoul F. Radioimmunotherapy in Oncology: overview of the last decade clinical trials. Cancers (Basel). 2021;13. https://doi.org/10.3390/CANCERS13215570.

3. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8. https://doi.org/10.1038/363446A0.

4. Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, et al. Emerging applications of nanobodies in cancer therapy. Int Rev Cell Mol Biol. 2022;369:143–99. https://doi.org/10.1016/bs.ircmb.2022.03.010.

5. D’Huyvetter M, De Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising candidate for HER2-Targeted Radionuclide Therapy in breast Cancer patients. J Nucl Med. 2021;62:1097–105. https://doi.org/10.2967/JNUMED.120.255679.